<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042379</url>
  </required_header>
  <id_info>
    <org_study_id>097517</org_study_id>
    <nct_id>NCT01042379</nct_id>
  </id_info>
  <brief_title>I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer</brief_title>
  <acronym>I-SPY</acronym>
  <official_title>I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QuantumLeap Healthcare Collaborative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QuantumLeap Healthcare Collaborative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further advance the ability to practice personalized medicine&#xD;
      by learning which new drug agents are most effective with which types of breast cancer tumors&#xD;
      and by learning more about which early indicators of response (tumor analysis prior to&#xD;
      surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are&#xD;
      predictors of treatment success.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I-SPY will compare the efficacy of novel drugs in combination with standard chemotherapy with&#xD;
      the efficacy of standard therapy alone. The goal is identify improved treatment regimens for&#xD;
      subsets on the basis of molecular characteristics (biomarker signatures) of their disease. As&#xD;
      described for previous adaptive trials, regimens that show a high Bayesian predictive&#xD;
      probability of being more effective than standard therapy will graduate from the trial with&#xD;
      their corresponding biomarker signature(s). Regimens will be dropped if they show a low&#xD;
      probability of improved efficacy with any biomarker signature. New drugs will enter as those&#xD;
      that have undergone testing complete their evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2010</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.</measure>
    <time_frame>Post surgery based on upto 24-week treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB).</measure>
    <time_frame>Blood and Tissue Collection: Baseline, Post-Randomization, Pre-AC, Pre- and Post-Surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms.</measure>
    <time_frame>Three- and Five-Year Post-surgery Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine incidence of adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities of each investigational agent tested.</measure>
    <time_frame>Post-Randomization, Pre-AC, Pre-Surgery, Post-Surgery upto One Year during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Volume</measure>
    <time_frame>Four time points during the on-study phase: Baseline, Post-randomization, Pre-AC treatment and Pre-Surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>27</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Tumors</condition>
  <condition>Angiosarcoma</condition>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>Hormone Receptor Positive Tumor</condition>
  <condition>Hormone Receptor Negative Tumor</condition>
  <condition>Early-stage Breast Cancer</condition>
  <condition>Locally Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel, Herceptin followed by Doxorubicin and Cyclophosphamide treatment depending on HR/HER-2 status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 386 with or without Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 479 plus Metformin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-2206 with or without Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-DM1 and Pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pertuzumab and Trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Novel Control Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganetespib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-888</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neratinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX3397</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab 4 cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Talazoparib plus Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patritumab with or without Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab 8 cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGN-LIV1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab plus Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD-101 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tucatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cemiplimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cemiplimab plus REGN3767</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trilaciclib with or without trastuzumab + pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYD985 ([vic-]trastuzumab duocarmazine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocrine Optimization Pilot: Amcenestrant Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocrine Optimization Pilot: Amcenestrant + Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocrine Optimization Pilot: Amcenestrant + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel Investigational Agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16</description>
    <arm_group_label>Standard Therapy</arm_group_label>
    <other_name>Paclitaxel (Taxol); Doxorubicin (Adriamycin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 with or without Trastuzumab</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>AMG 386 with or without Trastuzumab</arm_group_label>
    <other_name>AMG 386 (Trebananib); (Trastuzumab) Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 479 (Ganitumab) plus Metformin</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>AMG 479 plus Metformin</arm_group_label>
    <other_name>Ganitumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206 with or without Trastuzumab</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>MK-2206 with or without Trastuzumab</arm_group_label>
    <other_name>(Trastuzumab) Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 and Trastuzumab</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>AMG 386 with or without Trastuzumab</arm_group_label>
    <other_name>AMG 386 (Trebananib); Trastuzumab (Herceptin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-DM1 and Pertuzumab</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>T-DM1 and Pertuzumab</arm_group_label>
    <other_name>T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab and Trastuzumab</intervention_name>
    <description>Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization</description>
    <arm_group_label>Pertuzumab and Trastuzumab</arm_group_label>
    <other_name>Pertuzumab (Perjeta); Trastuzumab (Herceptin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganetespib</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Ganetespib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>ABT-888</arm_group_label>
    <other_name>Veliparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neratinib</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Neratinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX3397</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>PLX3397</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab - 4 cycle</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Pembrolizumab 4 cycle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib plus Irinotecan</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Talazoparib plus Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patritumab and Trastuzumab</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Patritumab with or without Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab - 8 cycle</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Pembrolizumab 8 cycle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-LIV1A</intervention_name>
    <description>Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16</description>
    <arm_group_label>SGN-LIV1A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab plus Olaparib</intervention_name>
    <description>Arm is closed.</description>
    <arm_group_label>Durvalumab plus Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-101 + Pembrolizumab</intervention_name>
    <description>Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for &gt;T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles</description>
    <arm_group_label>SD-101 + Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib plus trastuzumab and pertuzumab</intervention_name>
    <description>Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles</description>
    <arm_group_label>Tucatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles</description>
    <arm_group_label>Cemiplimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab plus REGN3767</intervention_name>
    <description>Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles</description>
    <arm_group_label>Cemiplimab plus REGN3767</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trilaciclib with or without trastuzumab + pertuzumab</intervention_name>
    <description>Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles&#xD;
For HER2+:&#xD;
Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization</description>
    <arm_group_label>Trilaciclib with or without trastuzumab + pertuzumab</arm_group_label>
    <other_name>Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYD985 ([vic-]trastuzumab duocarmazine)</intervention_name>
    <description>SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles</description>
    <arm_group_label>SYD985 ([vic-]trastuzumab duocarmazine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab</intervention_name>
    <description>For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle&#xD;
For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle</description>
    <arm_group_label>Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab</arm_group_label>
    <other_name>Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab</intervention_name>
    <description>For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle&#xD;
For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle</description>
    <arm_group_label>Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab</arm_group_label>
    <other_name>Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amcenestrant</intervention_name>
    <description>Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks</description>
    <arm_group_label>Endocrine Optimization Pilot: Amcenestrant Monotherapy</arm_group_label>
    <other_name>SAR439859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amcenestrant + Abemaciclib</intervention_name>
    <description>Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks</description>
    <arm_group_label>Endocrine Optimization Pilot: Amcenestrant + Abemaciclib</arm_group_label>
    <other_name>Amcenestrant (SAR439859), Abemaciclib (Verzenio)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amcenestrant + Letrozole</intervention_name>
    <description>Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks</description>
    <arm_group_label>Endocrine Optimization Pilot: Amcenestrant + Letrozole</arm_group_label>
    <other_name>Amcenestrant (SAR439859), Letrozole (Femara)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed invasive cancer of the breast&#xD;
&#xD;
          -  Clinically or radiologically measureable disease in the breast after diagnostic&#xD;
             biopsy, defined as longest diameter greater than or equal to 25 mm (2.5cm)&#xD;
&#xD;
          -  No prior cytotoxic regimens are allowed for this malignancy. Patients may not have had&#xD;
             prior chemotherapy or prior radiation therapy to the ipsilateral breast for this&#xD;
             malignancy. Prior bis-phosphonate therapy is allowed&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Willing to undergo core biopsy of the primary breast lesion to assess baseline&#xD;
             biomarkers&#xD;
&#xD;
          -  Non-pregnant and non-lactating&#xD;
&#xD;
          -  No ferromagnetic prostheses. Patients who have metallic surgical implants that are not&#xD;
             compatible with an MRI machine are not eligible.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent (I-SPY TRIAL&#xD;
             Screening Consent)&#xD;
&#xD;
          -  Eligible tumors must meet one of the following criteria: Stage II or III, or T4, any&#xD;
             N, M0, including clinical or pathologic inflammatory cancer or Regional Stage IV,&#xD;
             where supraclavicular lymph nodes are the only sites metastasis&#xD;
&#xD;
          -  Any tumor ER/PgR status, any HER-2/neu status as measured by local hospital pathology&#xD;
             laboratory and meets any tumor assay profile described in protocol section 4.1.2F&#xD;
&#xD;
          -  Normal organ and marrow function: Leukocytes ≥ 3000/μL, Absolute neutrophil count ≥&#xD;
             1500/μL, Platelets ≥ 100,000/μL, Total bilirubin within normal institutional limits,&#xD;
             unless patient has Gilbert's disease, for which bilirubin must be ≤ 2.0 x ULN,&#xD;
             AST(SGOT)/ALT (SGPT) ≤ 1.5 x institutional ULN, creatinine &lt; 1.5 x institutional ULN&#xD;
&#xD;
          -  No uncontrolled or severe cardiac disease. Baseline ejection fraction (by nuclear&#xD;
             imaging or echocardiography) must by ≥ 50%&#xD;
&#xD;
          -  No clinical or imaging evidence of distant metastases by PA and Lateral CXR,&#xD;
             Radionuclide Bone scan, and LFTs including total bilirubin, ALT, AST, and alkaline&#xD;
             phosphatase&#xD;
&#xD;
          -  Tumor assay profile must include on of the following: MammaPrint High, any ER status,&#xD;
             any HER2 status, or MammaPrint Low, ER negative (&lt;5%), any HER2 status, or MammaPrint&#xD;
             Low, ER positive, HER2/neu positive by any one of the three methods used (IHC, FISH,&#xD;
             TargetPrint™)&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
             (I-SPY 2 TRIAL Consent #2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any other investigational agents within 30 days of starting study treatment&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to the study agent or accompanying supportive medications.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Esserman, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meera Bose</last_name>
    <phone>415-514-6878</phone>
    <email>ispyadmin@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Smita Asare</last_name>
    <email>smita.asare@ispy2.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erica Stringer-Reasor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-822-6194</phone>
    </contact>
    <contact_backup>
      <phone>858-822-6194</phone>
      <email>CancerCTO@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Wallace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-443-4296</phone>
    </contact>
    <investigator>
      <last_name>Amy Jo Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-848-1622</phone>
    </contact>
    <investigator>
      <last_name>Anthony Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Burello, MS</last_name>
      <phone>203-737-2848</phone>
      <email>trisha.burrello@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Tara Snaft, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lajos Pusztai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minetta Liu, MD</last_name>
      <phone>202-444-3677</phone>
      <email>Liumc@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Claudine Isaacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heather Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kevin Kalinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-834-2756</phone>
    </contact>
    <investigator>
      <last_name>Rita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>708-327-3102</phone>
    </contact>
    <investigator>
      <last_name>Kathy S Albain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-626-8487</phone>
    </contact>
    <investigator>
      <last_name>Douglas Yee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Judy C Boughey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jesus D Anampa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meghana Trivedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Howell, MD</last_name>
      <phone>336-716-5440</phone>
      <email>anhowell@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Alexandra Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Institute (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-8573</phone>
    </contact>
    <investigator>
      <last_name>Zahi Mitri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (U Penn)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-614-1850</phone>
    </contact>
    <investigator>
      <last_name>Amy Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Brufsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Clinical Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amy Sanford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>27204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ingrid Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Health System</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.ispy2.org</url>
    <description>I-SPY 2 TRIAL Website</description>
  </link>
  <link>
    <url>http://d3ciwvs59ifrt8.cloudfront.net/6cac4f3d-e0de-4924-9f2a-9b5b95ea9a0d/25399142-2af5-4a8e-8a21-184e5fc141c7.pdf</url>
    <description>Abstract S5-02 SABCC 2014</description>
  </link>
  <link>
    <url>http://d3ciwvs59ifrt8.cloudfront.net/6cac4f3d-e0de-4924-9f2a-9b5b95ea9a0d/e8745ff8-6e60-412c-8e14-930a42d1f477.pdf</url>
    <description>Abstract CT227 AACR 2014</description>
  </link>
  <link>
    <url>http://d3ciwvs59ifrt8.cloudfront.net/6cac4f3d-e0de-4924-9f2a-9b5b95ea9a0d/30b6e099-e50c-48dd-a733-2ecb9f7bc6a3.pdf</url>
    <description>Abstract P1-14-03; SABCC 2015</description>
  </link>
  <reference>
    <citation>Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul;86(1):97-100. doi: 10.1038/clpt.2009.68. Epub 2009 May 13.</citation>
    <PMID>19440188</PMID>
  </reference>
  <reference>
    <citation>Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011 Dec 21;306(23):2608-9. doi: 10.1001/jama.2011.1837.</citation>
    <PMID>22187281</PMID>
  </reference>
  <results_reference>
    <citation>Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.</citation>
    <PMID>22649152</PMID>
  </results_reference>
  <results_reference>
    <citation>Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun;263(3):663-72. doi: 10.1148/radiol.12110748.</citation>
    <PMID>22623692</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28.</citation>
    <PMID>21796368</PMID>
  </results_reference>
  <results_reference>
    <citation>Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.</citation>
    <PMID>22198468</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 31, 2009</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Adaptive</keyword>
  <keyword>pCR</keyword>
  <keyword>Pathologic Complete Response</keyword>
  <keyword>Biomarkers signature</keyword>
  <keyword>MRI Volume</keyword>
  <keyword>Endocrine Therapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Veliparib</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
    <mesh_term>Trebananib</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

